SIM0686

SIM0686 is a clinical-stage **antibody-drug conjugate (ADC)** developed by Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group. It targets **FGFR2b (Fibroblast Growth Factor Receptor 2b)**, a transmembrane tyrosine kinase receptor overexpressed or gene-fused in several solid tumors. The ADC uses a proprietary platform to combine an FGFR2b-specific monoclonal antibody with a topoisomerase I inhibitor payload. SIM0686 is designed to deliver the cytotoxic agent directly to tumor cells expressing FGFR2b, thereby enhancing anti-tumor efficacy and reducing systemic toxicity. Its bystander effect allows it to impact FGFR2b-negative tumor cells in the vicinity as well. As of mid-2025, SIM0686 is undergoing Phase 1 clinical trials in patients with **locally advanced or metastatic solid tumors** positive for FGFR2b[1][3][9].